Satoshi Nakamoto Blog
Image default

Ex-Alembic executive pleads guilty in U.S. generic drug price-fixing scheme

WASHINGTON (Reuters) – A former executive of Alembic Pharmaceuticals Ltd pleaded guilty on Friday to participating in a scheme to fix prices for generic medicines.

The Justice Department said former executive Hector Armando Kellum had pleaded guilty to working to fix the prices of clobetasol, used to treat eczema and psoriasis, and nystatin triamcinolone cream, an anti-fungal drug that also has a corticosteroid.

Alembic’s website lists Kellum as a vice president of sales and marketing. Kellum, contacted through Alembic, did not respond to a request for comment.

The government said one of Kellum’s alleged co-conspirators was Ara Aprahamian, a former sales and marketing executive at Taro Pharmaceutical Industries Ltd, who was also indicted for price-fixing and bid-rigging.

U.S. drug pricing has become a political issue in recent years amid complaints that some drugs, including medicines on the market for decades, have seen sharp price increases.

Reporting by Diane Bartz; Editing by Tom Brown

Our Standards:The Thomson Reuters Trust Principles.

Source link

Related posts

Thousands expected to demonstrate Monday against Puerto Rico’s governor, hold general strike


New York jurors shown naked photos of Harvey Weinstein


Climate change’s fingerprints are on U.S. Midwest floods: scientists


Mother, daughter charged with slaying five family members in Pennsylvania


Women’s World Cup final draws 14.3 million U.S. viewers, but misses record


NBA great Kobe Bryant and daughter among nine killed in helicopter crash near Los Angeles